Oculis Holding AG - Ordinary shares (NQ:OCS)

19.33 +0.04 (+0.21%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Price and Volume

Volume	120,662
Open	19.45
Bid (Size)	19.27 (200)
Ask (Size)	19.33 (300)
Prev. Close	19.29
Today's Range	19.25 - 19.45
52wk Range	14.00 - 23.08
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

November 11, 2025

Via Benzinga

Oculis Holding AG (NASDAQ:OCS) Reports Q3 2025 Earnings Beat and Provides Key Clinical Pipeline Updates ↗

November 10, 2025

Oculis (OCS) beat Q3 2025 earnings estimates, extended cash runway into 2029, and advanced its late-stage ophthalmology pipeline with key clinical milestones ahead.

Via Chartmill

Performance

YTD	+14.2%	+14.2%
1 Month	-10.3%	-10.3%
3 Month	+8.7%	+8.7%
6 Month	-2.8%	-2.8%
1 Year	+30.7%	+30.7%

More News

Oculis Reports Q3 2025 Financial Results and Provides Company Update

November 10, 2025

From Oculis Holding AG

Via GlobeNewswire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Oculis to Participate in Upcoming November Investor Conferences

November 05, 2025

From Oculis Holding AG

Via GlobeNewswire

Uncovering Potential: Oculis Holding's Earnings Preview ↗

August 20, 2025

Via Benzinga

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

October 30, 2025

From Oculis Holding AG

Via GlobeNewswire

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

October 14, 2025

From Oculis Holding AG

Via GlobeNewswire

Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

October 08, 2025

Via Benzinga

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

October 06, 2025

From Oculis Holding AG

Via GlobeNewswire

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

September 22, 2025

From Oculis Holding AG

Via GlobeNewswire

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

September 04, 2025

From Oculis Holding AG

Via GlobeNewswire

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

September 01, 2025

From Oculis Holding AG

Via GlobeNewswire

Oculis to Participate in Upcoming September Investor Conferences

August 28, 2025

From Oculis Holding AG

Via GlobeNewswire

This CoreWeave Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

August 27, 2025

Via Benzinga

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

August 25, 2025

From Oculis Holding AG

Via GlobeNewswire

Oculis Reports Q2 2025 Financial Results and Provides Company Update

August 21, 2025

From Oculis Holding AG

Via GlobeNewswire

Earnings Scheduled For August 21, 2025 ↗

August 21, 2025

Via Benzinga

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 12, 2025

From Oculis Holding AG

Via GlobeNewswire

Oculis Upsized Loan Facility to Access up to CHF 100 million

August 01, 2025

From Oculis Holding AG

Via GlobeNewswire

Oculis Publishes Results of 2025 Annual General Meeting

June 05, 2025

From Oculis Holding AG

Via GlobeNewswire

Oculis to Participate in Upcoming June Investor Conferences

June 03, 2025

From Oculis Holding AG

Via GlobeNewswire

Oculis Publishes Invitation to the Annual General Meeting

May 09, 2025

From Oculis Holding AG

Via GlobeNewswire

Dave To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday ↗

May 09, 2025

Via Benzinga

Oculis Reports Q1 2025 Financial Results and Provides Company Update

May 08, 2025

From Oculis Holding AG

Via GlobeNewswire

Frequently Asked Questions

Is Oculis Holding AG - Ordinary shares publicly traded?

Yes, Oculis Holding AG - Ordinary shares is publicly traded.

What exchange does Oculis Holding AG - Ordinary shares trade on?

Oculis Holding AG - Ordinary shares trades on the Nasdaq Stock Market

What is the ticker symbol for Oculis Holding AG - Ordinary shares?

The ticker symbol for Oculis Holding AG - Ordinary shares is OCS on the Nasdaq Stock Market

What is the current price of Oculis Holding AG - Ordinary shares?

The current price of Oculis Holding AG - Ordinary shares is 19.33

When was Oculis Holding AG - Ordinary shares last traded?

The last trade of Oculis Holding AG - Ordinary shares was at 11/25/25 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.